Centenara Labs, formerly Rejuveron, rebrands to focus on anti-ageing research
FiercePharma - 23-Sep-2024Their lead treatment, EA-2353, shows promising safety results for retinitis pigmentosa
Join the club for FREE to access the whole archive and other member benefits.
Chief Executive Officer at the Rejuveron
Aksana brings 10+ years of experience in the life science and healthcare industry, including early-stage business development, company building, and venture. At Rejuveron she oversees investments, deal sourcing and contributes to strategic expansion of our portfolio companies.
Labokha's work experience spans across research, business development, investment, and executive roles, demonstrating their expertise and knowledge in the life sciences industry.
Aksana Labokha earned a Doctor of Life Sciences degree in Biochemistry from The University of Göttingen in the years spanning from 2005 to 2010. Prior to that, from 2000 to 2005, they completed their Master's degree in Molecular Medicine and Radiobiology at International Sakharov Environmental University. Aksana also obtained a certification in Healthcare Business Development & Licensing Training from PHARMACEUTICAL LICENSING GROUP LIMITED in March 2018.
Visit website: https://rejuveron.com/en/who-we-are/people
See also: Rejuveron - Company that develops and invests in drugs and technologies which prolong human lifespan.
Details last updated 05-Aug-2023
28-Aug-2023 to 01-Sep-2023
Event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen
Their lead treatment, EA-2353, shows promising safety results for retinitis pigmentosa